




RealRate

PHARMACEUTICAL 2021

Acadia Pharmaceuticals INC
Rank 132 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Acadia Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acadia Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 89% points. The greatest weakness of Acadia Pharmaceuticals INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 323%, being 67% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	717,616
Cost of Goods Sold	10,211
Intangible Assets	1,108
Liabilities, Current	105,967
Liabilities, Non-Current	49,640
Other Assets	54,731
Other Compr. Net Income	-261
Other Expenses	10,950
Other Liabilities	0
Other Net Income	5,613
Other Revenues	441,755
Property and Equipment	9,161
Research and Development	319,130
Selling, General and Administrative Expense	388,661

Output Variable	Value in 1000 USD
Assets	782,616
Liabilities	155,607
Expenses	728,952
Revenues	441,755
Stockholders Equity	627,009
Net Income	-281,584
Comprehensive Net Income	-281,714
BaseVar	1,057,402
ECR before Limited Liability	231%
Economic Capital Ratio	323%